Advanced COVID Management
Welcome and thank you …
February 2020 onwards has seen a tremendous effort from you, with disruption to your personal and professional life that is seldom recognised by others. It has been a hard journey to this point but what is clear is that we need the support of all disciplines of healthcare personnel to manage the high burden of COVID patients.
Thank you for your hard work and dedication, congratulations for wishing to learn yet another skill to add to your excellent clinical repertoire, COVID Non-invasive Ventilation (NIV)!
Sincerest gratitude to Dr Sadia Khan, Dr Orhan Orhan and many others who have helped designed and produce this content and app.
Dr Ryan Dhunnookchand, on behalf of the Acute COVID app team
Respiratory Registrar ST7 & Education Fellow
Chelsea and Westminster Hospital NHS Foundation Trust
Venous Thromo-embolic Prevention (VTE)
COVID Tocilizumab
(IL-6 inhibitor)
COVID Remdesivir
(Viral RNA polymerase inhibitor)
Anti-COVID therapy is a fast and dynamic changing landscape, consideration should be given to clinical suitability and eligibility to newer classes of drugs.
Last updated: December 2020.
Anti-COVID Therapies
COVID Microbial Therapy Review (24-48 hours)
Review of progress and improving clinical state should include further rationalisation of unnecessary medications including antibiotics if ‘Procalcitonin’ is negative and clinical state deems appropriate..
Last updated: December 2020.
Antibiotics
Consideration should be given to rationalising antibiotic prescriptions in accordance with good antimicrobial stewardship.
Data from the Chelsea and Westminster cohort and nationally/internationally suggest less than 10%, and probably more than 5% have bacterial/fungal pulmonary co-infection on presentation. Some patients can (rarely) present with COVID-19 plus another systemic infection/sepsis.
Prescribe according to local current guidelines.
Last updated: December 2020.
COVID In-Hospital Treatment
